Skip Nav Destination
            
    
            
 
    
    
        
            
                
                
                    
                    
                        
                    
                
                
                    
                        
                        
                            
                        
                    
            
        
    
    
    
    
        
            
        
        
    
        
    
    
    
 
    
                
                    
            
    
        
    
    
                    
        
        
     
    
                    
        
                    
        
        Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis
        
        
            
        
    
        
                
            
    
    
    
        
        
     
    
                    
        
                    
        
        Th17 immune microenvironment in Epstein-Barr virus–negative Hodgkin lymphoma: implications for immunotherapy
        
        
            
        
    
        
                
            
    
    
    
        
        
     
    
                     
    
                    
        
                    
        
        HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity
        
        
            
        
    
        
                
            
    
    
    
        
        
     
    
 
    
            
    
        
    
         
 
    
    
        
    
            
    
        
    
    
    
        
    
    
    
            
    
                    
 
    
    
 
    
    
    
        
    
    
    
            
        
            
    
        
        
    
             
            
             
            
             
        
    
 
    
    
 
    
    
        
    
    
    
            
    
                    
 
    
    
 
    
    
 
    
    
    
    
        
    Issue Archive
Table of Contents
EXCEPTIONAL CASE REPORTS
CLINICAL TRIALS AND OBSERVATIONS
        
        Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis
        
        
            
        
                    
                        Clinical Trials & Observations
                    
        
            
    
        
            Prajwal Boddu,Hagop M. Kantarjian,Guillermo Garcia-Manero,Farhad Ravandi,Srdan Verstovsek,Elias Jabbour,Gautam Borthakur,Marina Konopleva,Kapil N. Bhalla,Naval Daver,Courtney D. DiNardo,Christopher B. Benton,Koichi Takahashi,Zeev Estrov,Sherry R. Pierce,Michael Andreeff,Jorge E. Cortes,Tapan M. Kadia
            
        
    
            LYMPHOID NEOPLASIA
        
        Th17 immune microenvironment in Epstein-Barr virus–negative Hodgkin lymphoma: implications for immunotherapy
        
        
            
        
                    
                        Clinical Trials & Observations
                    
        
            
    
        
            Amy S. Duffield,Maria Libera Ascierto,Robert A. Anders,Janis M. Taube,Alan K. Meeker,Shuming Chen,Tracee L. McMiller,Neil A. Phillips,Haiying Xu,Aleksandra Ogurtsova,Alan E. Berger,Drew M. Pardoll,Suzanne L. Topalian,Richard F. Ambinder
            
        
    
            RED CELLS, IRON, AND ERYTHROPOIESIS
TRANSPLANTATION
        
        HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity
        
        
            
        
                    
                        Clinical Trials & Observations
                    
        
            
    
        
            Michael A. Spinner,Marcelo Fernández-Viña,Lisa E. Creary,Olivia Quinn,Linda Elder,Sally Arai,Laura J. Johnston,Everett H. Meyer,David B. Miklos,Lori S. Muffly,Robert S. Negrin,Judith A. Shizuru,Wen-Kai Weng,Ginna G. Laport,Samuel Strober,Robert Lowsky,Andrew R. Rezvani
            
        
    
            - 
        
            Cover Image
        
        Cover Image![issue cover]()  COVER FIGURE 
 The immunosuppressive ligand PD-L1 is abundantly expressed by Hodgkin/Reed-Sternberg cells and infiltrating immune cells in classic Hodgkin lymphoma. Brown staining with immunohistochemistry identifies the PD-L1 protein. See the article by Duffield et al.
- PDF Icon Front MatterFront Matter
- PDF Icon Editorial BoardEditorial Board
Advertisement intended for health care professionals
Advertisement intended for health care professionals
 
                    




